TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 607-618

  Brachova, Pavla ^a,b,c   Mueting, Samuel R ^a   Carlson, Matthew J ^a   Goodheart, Michael J ^a,b   Button, Anna M ^b   Mott, Sarah L ^b   Dai, Donghai ^a   Thiel, Kristina W ^a   Devor, Eric J ^a   Leslie, Kimberly K ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoresistance; Gain of function; Oncomorphic p53 mutation; Ovarian cancer; TP53

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; OXALIPLATIN; PACLITAXEL; PROTEIN P53; BRIDGED COMPOUND; PLATINUM; TAXANE; TAXOID; TP53 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CLONOGENESIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; POINT MUTATION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; AGED; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; BRIDGED COMPOUNDS; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84918502971     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2747     Document Type: Article

References (40)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
3. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
4. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007.
5. Freed-Pastor WA and Prives C: Mutant p53: one name, many proteins. Genes Dev 26: 1268-1286, 2012.
6. Brachova P, Thiel KW and Leslie KK: The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci 14: 19257-19275, 2013.
7. Hall J, Paul J and Brown R: Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med 6: 1-20, 2004.
8. Meng X, Dizon DS, Yang S, et al: Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int 2013: 828165, 2013.
9. Meng X, Laidler LL , Kosmacek EA , et al: Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecol Oncol 128: 461-469, 2013.
10. Hanel W, Marchenko N, Xu S, Xiaofeng Yu S, Weng W and Moll U: Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20: 898-909, 2013.
11. Gaiddon C, Lokshin M, Ahn J, Zhang T and Prives C: A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874-1887, 2001.
12. Xie TX, Zhou G, Zhao M, et al: Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope 123: 1416-1423, 2013.
13. Scian MJ, Stagliano KE, Deb D, et al: Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23: 4430-4443, 2004.
14. Lang GA , Iwakuma T, Suh YA , et al: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872, 2004.
15. Olive KP, Tuveson DA, Ruhe ZC, et al: Mutant p53 gain of function in two mouse models of Li-F raumeni syndrome. Cell 119: 847-860, 2004.
16. Wang YX and Kotlikoff MI: Inactivation of calcium-activated chloride channels in smooth muscle by calcium/calmodulin-dependent protein kinase. Proc Natl Acad Sci USA 94: 14918-14923, 1997.
17. Ko JL , Chiao MC, Chang SL, et al: A novel p53 mutant retained functional activity in lung carcinomas. DNA Repair (Amst) 1: 755-762, 2002.
18. Sproston AR , Boyle JM, Heighway J, Birch JM and Scott D: Fibroblasts from Li-F raumeni patients are resistant to low dose-rate irradiation. Int J Radiat Biol 70: 145-150, 1996.
19. Song H, Hollstein M and Xu Y: p53 gain-of-function cancer mutants induce genetic instability by inactivating AT M. Nat Cell Biol 9: 573-580, 2007.
20. Krepulat F, Löhler J, Heinlein C, Hermannstädter A, Tolstonog GV and Deppert W: Epigenetic mechanisms affect mutant p53 transgene expression in WA P-mutp53 transgenic mice. Oncogene 24: 4645-4659, 2005.
21. Bergamaschi D, Gasco M, Hiller L, et al: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer cell 3: 387-402, 2003.
22. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC and Kaelin WG Jr: Chemosensitivity linked to p73 function. Cancer cell 3: 403-410, 2003.
23. Duan W, Ding H, Subler MA, et al: Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21: 7831-7838, 2002.
24. Morselli E, Tasdemir E, Maiuri MC, et al: Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell cycle 7: 3056-3061, 2008.
25. Bourdon JC , Fernandes K, Murray-Zmijewski F, et al: p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122-2137, 2005.
26. Hofstetter G, Berger A, Fiegl H, et al: Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 29: 1997-2004, 2010.
27. Holmila R, Fouquet C, Cadranel J, Zalcman G and Soussi T: Splice mutations in the p53 gene: case report and review of the literature. Hum Mutat 21: 101-102, 2003.
28. Sameshima Y, Akiyama T, Mori N, et al: Point mutation of the p53 gene resulting in splicing inhibition in small cell lung carcinoma. Biochem Biophys Res Commun 173: 697-703, 1990.
29. Bodnar L, Stanczak A, Cierniak S, et al: Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res 7: 16, 2014.
30. Kang HJ, Chun SM, Kim KR, Sohn I and Sung CO : Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PloS ?ne 8: e72609, 2013.
31. Monti P, Campomenosi P, Ciribilli Y, et al: Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22: 5252-5260, 2003.
32. Liu G, McDonnell TJ , Montes de Oca Luna R, et al: High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97: 4174-4179, 2000.
33. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ and Buller RE : p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 9: 1028-1032, 2003.
34. Schmider A, Gee C, Friedmann W, et al: p21 (WAF 1/CI P1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol 77: 237-242, 2000.
35. Rojas M, Yao S and Lin YZ: Controlling epidermal growth factor (EGF )-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271: 27456-27461, 1996.
36. Ludes-Meyers JH, Subler MA, Shivakumar CV, et al: Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16: 6009-6019, 1996.
37. Di Agostino S, Strano S, Emiliozzi V, et al: Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer cell 10: 191-202, 2006.
38. Wong KK, Izaguirre DI, Kwan SY, et al: Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130: 565-569, 2013.
39. Willis A, Jung EJ, Wakefield T and Chen X: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23: 2330-2338, 2004.
40. Xu J, Qian J, Hu Y, et al: Heterogeneity of Li-F raumeni syndrome links to unequal gain-of-function effects of p53 mutations. Sci Rep 4: 4223, 2014.